Whan In Pharm (016580) Fundamentals 2026 — P/E 10.6x, Revenue Analysis | SniperIQ
Whan In Pharm (016580) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩149.0B, trading at ₩9760.00 on the KSC. This SniperIQ fundamentals page covers Whan In Pharm's valuation (P/E 10.6x, P/B 0.4x), profitability (net margin 6.0%), revenue (₩255.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Whan In Pharm's market cap?
Whan In Pharm (016580) has a market capitalization of approximately ₩149.0B, trading at ₩9760.00 on the KSC. Market cap moves with the live share price.
What is Whan In Pharm's P/E ratio?
Whan In Pharm's trailing twelve-month P/E ratio is 10.6x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Whan In Pharm?
Whan In Pharm runs a net profit margin of 6.0%, a gross margin of 43.4%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Whan In Pharm generate?
Whan In Pharm reported revenue of ₩255.2B for fiscal year 2025, with net income of ₩13.6B and earnings per share (EPS) of 857. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Whan In Pharm pay a dividend?
Whan In Pharm offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Whan In Pharm financially healthy?
Whan In Pharm carries a debt-to-equity ratio of 0.00x and a current ratio of 4.10x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Whan In Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Whan In Pharm (016580) the key facts are: market cap ₩149.0B, P/E 10.6x, revenue ₩255.2B, 52-week range 9160-12700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Whan In Pharm's full fundamentals live
Get Whan In Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.